Alkermes plc (NASDAQ: ALKS) today announced that data for the two-month dosing option of ARISTADA� (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia will be presented at the 16th International Congress ...
Alkermes (NASDAQ:ALKS), a biopharmaceutical company that specializes in extended-release drug delivery technology, reported third-quarter results on Nov. 2 and provided investors with an update on its pipeline.
Alkermes tested ALKS 5461 in patients with major depressive disorder who haven't been helped by other drugs. At the higher dose, ALKS 5461 improved symptoms of depression -- based on two different scales used by doctors -- compared with placebo.
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas.